Close Menu

Fluidigm

Mass cytometry revenues increased 28 percent to $17.5 million year over year, but microfluidics revenues dropped 16 percent to $10.7 million.

Year-over-year revenues increased on strong demand for the company's Helios and Hyperion imaging mass cytometry systems.

The index, which underperformed the Dow Jones and the Nasdaq, fell nearly 3 percent in April.

The Maxpar Direct Immune Profiling System could lower the threshold to doing mass cytometry due to ease of use, a core lab director said.

Natera and Veracyte both received positive news regarding local coverage determinations from Medicare contractors, while the catalysts for Fluidigm's rise were unclear.

Speakers at this year's ABRF meeting described how they used single-cell tools in combination with other single-cell approaches and other methods.

UBS granted Agilent a Buy rating and a $92 price target; Fluidigm a Neutral rating and a $14 price target; and Qiagen a Neutral rating with a $42 price target.

The index — which outperformed the Dow Jones, the Nasdaq, and the Biotechnology Index this month — gained more than 8 percent.

Revenues from mass cytometry instruments, consumables, and service increased 48 percent to $19.1 million from $12.9 million in Q4 2017.

Pages

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.